

Our Ref: ID 1723

NHS Wirral Clinical Commissioning Group
Marriss House
Hamilton Street
Birkenhead
Wirral
CH41 5AL
Tel: 0151 651 0011

Re: Freedom of Information Request - Dermatology and Rheumatology services

Thank you for your request for information made under the Freedom of Information Act 2000, which was received into this office on 22nd July 2020.

You Asked for:

1. Has a shared care agreement/arrangement been established between the Clinical Commissioning Group (CCG), secondary care and local primary care services (e.g. general practitioners) for the treatment of Psoriasis and Psoriatic Arthritis?
2. If you answered 'Yes' to Q1, what are the names and/or roles of the signatories of the shared care agreement?
If you answered 'Yes' to Q1, which of the following medicines can be prescribed within the shared care agreement?

Psoriasis			Psoriatic Arthritis		
Apremilast	Methotrexate	Dimethyl Fumarate	Apremilast	Methotrexate	Tofacitinib

3. How many consultant-led **community-based** Dermatology or Rheumatology services has your CCG commissioned that treat Psoriasis or Psoriatic Arthritis?
4. Who/where are these services commissioned from?
5. Which of the following treatments can be prescribed by these services?

Treatment	Y/N
Methotrexate	
Ciclosporin	
PUVA	
Apremilast (PDE4i)	
Dimethyl Fumarate (Psoriasis)	
Tofacitinib (Psoriatic Arthritis)	
Biologics* (*See annex 1 for list of biologic therapies)	

6. How many GPwERs has your CCG commissioned for Dermatology, and Rheumatology? Please provide the geographical locations of these commissioned services.

	How many GPwERs has your CCG commissioned?	Please provide the geographic locations of these commissioned services
--	--	--

Dermatology		
Rheumatology		

7. Are digital services commissioned by the CCG for the management of Dermatology and Rheumatology? If so, please specify the digital services provided? This may include tele-dermatology services (various levels) and/or virtual clinics.

	Dermatology	Rheumatology
Are digital services commissioned by the CCG within Dermatology and Rheumatology in your area? (Y, N, N/A)		
Please specify the type and level of digital services provided?		

Annex 1

adalimumab (Amgevita®, Humira®, Hyrimoz® or Imraldi®)
brodalumab (Siliq®)
certolizumab (Cimzia®)
etanercept (Benepali®)
golimumab (Simponi®)
guselkumab (Tremfya®)
infliximab (Remicade®)
ixekizumab (Taltz®)
risankizumab (Skyrizi®)
secukinumab (Cosentyx®)
tildrakizumab (Ilumya®)
ustekinumab (Stelara®)

Our Response:

- 1) Information for the treatment of psoriasis and psoriatic arthritis is as per the Pan Mersey Area Prescribing Committee. I have included links below to provide further information:
- <https://www.panmerseyapc.nhs.uk/media/2331/azathioprinewirral.pdf>
 - <https://www.panmerseyapc.nhs.uk/media/2332/ciclosporinwirral.pdf>
 - <https://www.panmerseyapc.nhs.uk/media/2333/leflunomidewirral.pdf>
 - <https://www.panmerseyapc.nhs.uk/media/2335/methotrexatewirral.pdf>

- <https://www.panmerseyapc.nhs.uk/media/2336/mycophenolatewirral.pdf>
- 2) NHS Wirral Clinical Commissioning Group (CCG) have approved the shared care guidelines and Methotrexate, within NHS Wirral CCG, is as per the Pan Mersey Area Prescribing Committee. Please click the link provided below for more information:
<https://www.panmerseyapc.nhs.uk/media/2335/methotrexatewirral.pdf>
 - 3) 0.
 - 4) Not applicable.
 - 5) In reference to Rheumatology, the response is not applicable, however, regarding Dermatology, please see the answers to both question 1 and 2.
 - 6) 0.
 - 7) No.

Addition note: There is also further information on the Pan Mersey website for:

- Apremilast
<https://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=10&SubSectionRef=10.01.03&SubSectionID=E150&drugmatch=5444#5444>
- Dimethyl fumarate
<https://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=13&SubSectionRef=13.05.02&SubSectionID=A100&drugmatch=4999#4999>
- Tofacitinib
<https://formulary.panmerseyapc.nhs.uk/chaptersSubDetails.asp?FormularySectionID=10&SubSectionRef=10.01.03&SubSectionID=E150&drugmatch=5515#5515>
- For your information the Pan Mersey PSORIASIS in adults, sequential use of biological agents is below:
https://www.panmerseyapc.nhs.uk/media/2132/psoriasis_biologics.pdf?UNLID=2709850402020724142334

We hope this information is useful, however if you require any further information please do not hesitate to contact a member of the Corporate Affairs Team (contact details at the top of this letter)

Re- Use of Information

Most of the information that we provide in response to Freedom of Information Act 2000 requests will be subject to copyright protection. In most cases the copyright will be owned by Wirral Clinical Commissioning Group. The copyright in other information may be owned by another person or organisation, as indicated on the information itself.

You are free to use any information supplied for your own non-commercial research or private study purposes. The information may also be used for any other purpose allowed by a limitation or exception in copyright law, such as news reporting. However, any other type of re-use, for example by publishing the information in analogue or digital form, including on the internet, will require the permission of the copyright owner.

For information where the copyright is owned by Wirral Clinical Commissioning Group please e-mail foirequests.nhswirralccg@nhs.net to request a reuse licence.

For information where the copyright is owned by another person or organisation you must apply to the copyright owner to obtain their permission.